palmidrol has been researched along with Myasthenia Gravis in 1 studies
palmidrol: a cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection
palmitoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of palmitic (hexadecanoic) acid.
Myasthenia Gravis: A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Onesti, E | 1 |
| Frasca, V | 1 |
| Ceccanti, M | 1 |
| Tartaglia, G | 1 |
| Gori, MC | 1 |
| Cambieri, C | 1 |
| Libonati, L | 1 |
| Palma, E | 1 |
| Inghilleri, M | 1 |
1 trial available for palmidrol and Myasthenia Gravis
| Article | Year |
|---|---|
Short-Term Ultramicronized Palmitoylethanolamide Therapy in Patients with Myasthenia Gravis: a Pilot Study to Possible Future Implications of Treatment.
Topics: Amides; Cannabinoid Receptor Agonists; Ethanolamines; Fatigue; Female; Follow-Up Studies; Humans; Ma | 2019 |